Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

Nature

Volumn 456, Issue 7222, 2008, Pages 663-666

  Hurtado, Antoni ^a   Holmes, Kelly A ^a   Geistlinger, Timothy R ^b   Hutcheson, Iain R ^c   Nicholson, Robert I ^c   Brown, Myles ^b   Jiang, Jie ^d   Howat, William J ^a   Ali, Simak ^d   Carroll, Jason S ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; TAMOXIFEN; TRANSCRIPTION FACTOR PAX2; TRASTUZUMAB;

CANCER; GENE EXPRESSION; HORMONE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 57349113761     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07483     Document Type: Article

References (30)

1. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev. 2, 101-112 (2002).
2. Carroll, J. S. et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genet. 38, 1289-1297 (2006).
3. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43 (2005).
4. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008).
5. Muratovska, A. et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22, 7989-7997 (2003).
6. Wu, H. et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981-987 (2005).
7. Clarke, R. et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53, 25-71 (2001).
8. Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353-361 (2003).
9. Benz, C. C. et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85-95 (1992).
10. Bates, N. P. & Hurst, H. C. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15, 473-481 (1997).
11. Frasor, J. et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64, 1522-1533 (2004).
12. Kun, Y. et al. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum. Mol. Genet. 12, 3245-3258 (2003).
13. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
14. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997).
15. Torres-Arzayus, M. I. et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274 (2004).
16. Fereshteh, M. P. et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res. 68, 3697-3706 (2008).
17. Louie, M. C. et al. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell. Biol. 24, 5157-5171 (2004).
18. Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 (2003).
19. Johnston, S. R. et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55, 3331-3338 (1995).
20. Green, K. A. & Carroll, J. S. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nature Rev. 7, 713-722 (2007).
21. Zhou, Y. et al. The NFκB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer 12 (Suppl 1), S37-S46 (2005).
22. Clark, J. et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosom. Cancer 34, 104-114 (2002).
23. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 8, 191-195 (2001).
24. Dowsett, M. et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 61, 8452-8458 (2001).
25. Jiang, J. et al. Phosphorylation of estrogen receptor-α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 13, 5769-5776 (2007).
26. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652-1662 (2005).
27. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
28. Johnson, W. E. et al. Model-based analysis of tiling-arrays for ChIP-chip. Proc. Natl Acad. Sci. USA 103, 12457-12462 (2006).
29. Carroll, J. S. et al. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275, 38221-38229 (2000).
30. Hagege, H. et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nature Protocols 2, 1722-1733 (2007).